Grazioplene, Rachael G. http://orcid.org/0000-0001-8708-4531
DeYoung, Colin G.
Hampson, Michelle
Anticevic, Alan
Pittenger, Christopher http://orcid.org/0000-0003-2117-9321
Article History
Received: 4 November 2021
Revised: 5 May 2022
Accepted: 30 May 2022
First Online: 10 August 2022
Conflict of interest
: Dr. Pittenger has served as a consultant and received compensation for Biohaven Pharmaceuticals, Ceruvia Life Sciences, Freedom Biotech, Transcend Therapeutics, and he has also received research support from Biohaven Pharmaceuticals and Transcend Therapeutics. Dr Anticevic consults for and holds equity with Neumora Therapeutics, Inc., co-founded Manifest Technologies, Inc., and is a co-inventor on the following patents: Anticevic A, Murray JD, Ji JL: Systems and Methods for Neuro-Behavioral Relationships in Dimensional Geometric Embedding (N-BRIDGE), PCT International Application No. PCT/US2119/022110, filed March 13, 2019 and Murray JD, Anticevic A, Martin, WJ: Methods and tools for detecting, diagnosing, predicting, prognosticating, or treating a neurobehavioral phenotype in a subject, U.S. Application No. 16/149,903 filed on October 2, 2018, U.S. Application for PCT International Application No. 18/054,009 filed on October 2, 2018. Dr. Grazioplene, Dr. DeYoung, and Dr. Hansen declare no potential conflict of interest.